Filters

Clear All
Filters

Filters

Clear All

Date Range

Type of Content

Author

Category

Displaying 11 - 20 of 29 results
Study
Trade and Economic Benefits of Enhanced Intellectual Property Protection for Pharmaceuticals in Canada

Trade and Economic Benefits of Enhanced Intellectual Property Protection for Pharmaceuticals in Canada

| by: Nadeem Esmail, Kristina M.L. Acri, née Lybecker, and Laura Dawson
Study
Bulk Purchase of Pharmaceuticals: The Experiences of the United States, Europe, and New Zealand

Bulk Purchase of Pharmaceuticals: The Experiences of the United States, Europe, and New Zealand

| by: Kristina M.L. Acri, née Lybecker
Commentary
Ottawa’s pharmacare plan would likely reduce drug coverage for millions of Canadians

Appeared in the Hill Times

| by: Kristina M.L. Acri, née Lybecker
Commentary
National pharmacare program—the threat to patients and innovation
| by: Kristina M.L. Acri, née Lybecker
Commentary
Pandemic showed that Canada needs a thriving biopharmaceutical industry
| by: Kristina M.L. Acri, née Lybecker
Commentary
Proposed ‘drug price’ changes threaten access for Canadian patients
| by: Kristina M.L. Acri, née Lybecker
Commentary
Trudeau government move undermines COVID-19 response

Appeared in the Appeared in National Newswatch

| by: Kristina M.L. Acri, née Lybecker
Commentary
Trade deal will hurt—not help—COVID vaccine mission

Appeared in the Vancouver Province

| by: Kristina M.L. Acri, née Lybecker
Commentary
USMCA will stunt potentially lifesaving innovation

Appeared in the Medicine Hat News

| by: Kristina M.L. Acri, née Lybecker
Commentary
Pharmacare plan will likely limit drug access and hurt patients

Appeared in the New Brunswick Telegraph-Journal

| by: Kristina M.L. Acri, née Lybecker